Novartis | NOVN - Los Gastos De Explotación





Los Gastos De Explotación Cambio Fecha
AbbVie USD 10.27B 1000K 2026-06
Alcon AG USD 2.78B 370M 2026-06
Almirall EUR 531.16M 13.76M 2026-06
Amgen USD 11.69B 6.9B 2026-06
AstraZeneca USD 12.22B 4.04B 2026-06
Autolus Therapeutics Ltd USD 85.73M 11.02M 2026-03
Bayer EUR 10.04B 168M 2026-06
Biogen USD 2.98B 1.02B 2026-06
Bristol-Myers Squibb USD 22.32B 2.25B 2026-06
Eli Lilly USD 10.52B 496M 2026-06
Fresenius EUR 5.23B 9M 2026-06
Fresenius Medical Care EUR 4.32B 20.7M 2026-06
Genmab DKK 748M 77M 2026-06
Gilead Sciences USD 3.95B 19.57B 2026-06
GlaxoSmithKline GBP 5.8B 468M 2026-06
GRIFOLS EUR 1.55B 94M 2026-06
Hikma Pharmaceutical USD 1.34B 702M 2025-12
J&J USD 17.83B 388M 2026-06
Lakefront Biotherapeutics EUR 55.62M 14.56M 2026-06
Lonza CHF 2.9B 184M 2025-06
Merck EUR 4.34B 249M 2026-06
Merck USD 15.77B 2.4B 2026-06
Novartis USD 10.2B 912M 2026-06
Novartis USD 9.29B 507M 2026-03
Novo Nordisk DKK 44.73B 7.52B 2026-06
Orion EUR 345M 42.1M 2026-06
Pfizer USD 85.19B 4.91B 2026-06
Philips EUR 3.75B 147M 2026-06
Recordati EUR 493.59M 11.28M 2026-06
Regeneron Pharmaceuticals USD 31.71B 287.8M 2026-06
Roche Holding CHF 18.9B 2.12B 2026-06
Sanofi EUR 9.92B 607M 2026-06
UCB EUR 2.96B 196M 2025-12